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number of other medical innovations for prosthesis are now considered straightforward procedures. 
Today we have even realised the potential for microchip implants to be embedded inside the body of 
humans for the purpose of acting as unique lifetime identifiers (ULI). Tiny radiofrequency identification 
(RFID) devices are now being utilised to store a unique 16-digit identification number. 
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Microchip implants for humans are not new. The installation of pacemakers in 
humans and a great number of other medical innovations for prosthesis are now 
considered straightforward procedures. Today we have even realised the potential for 
microchip implants to be embedded inside the body of humans for the purpose of 
acting as unique lifetime identifiers (ULI). Tiny radiofrequency identification (RFID) 
devices are now being utilised to store a unique 16-digit identification number.  
 
A significant paradigm shift has occurred in ‘how’ technology is being utilised by 
humans and ‘where’ it is being applied, requiring a commensurate ethical response 
from the broader community. For instance, what does it mean for technology to be 
embedded beneath the skin in a perfectly healthy human being for the purposes of 
‘easy’ identification or even amplification? Is an implant for non-medical purposes a 
basic breach in a human’s rights? Are implant IDs, even if consent has been granted 
by the recipient, in direct conflict with a State’s privacy laws? And what happens if an 
implant cannot be removed “on demand” because it has become intertwined with 
tissue in the body? 
 
It is estimated that there are over two thousand recipients of these tiny identification 
devices, most of which are sourced back to the Food and Drug Administration 
approved products of the VeriChip Corporation, based in the United States. The 
premier implantable VeriChip is used for the VeriMed application, namely patient 
identification. There are over 900 registered medical facilities that are now equipped 
with VeriChip readers. The VeriMed system claims to overcome the problems often 
associated with ‘at-risk’ individuals. For example, to aid patients in times of crisis- if 
they have collapsed, suffered memory loss, are unable to communicate, or have a 
complex medical history they cannot recollect.  
 
Corporate marketing identifies the following benefits of the VeriMed system: rapid 
identification in the emergency response (ER) room, instant medical record access, 
and improved emergency response. The chip simply stores a unique identification 
number, and associated medical records are stored in a secure global Verichip 
subscriber (GVS) registry database. The chip is inserted through a basic medical 
procedure, in the subdermal layer of the skin in the left or right upper arm, much as in 
the case of dog or cat implant. VeriChip’s other non-implantable applications are 
related to infant protection, wander prevention, and emergency management among 
others. 
One of the major concerns of the VeriChip, despite its FDA approval, is that the 
actual chip consists of a tissue-bonding cap that is designed to prevent the chip from 
moving around once it has been implanted inside the body. A series of veterinary and 
toxicology studies have found that chip implants, similar to the VeriChip, had caused 
malignant tumours in animals. The CEO of the VeriChip Corporation recently refuted 
the claims of the potential for tumours in humans, stating that the technology had 
been used for more than 15 years, and that the company had received no complaints 
about from VeriMed subscribers about the FDA approved anti-migration caps.  
 
RFID do-it-yourselfer implantees, like Amal Graafstra, have indicated that the 
problem with the VeriChip is the depth of the implantation, and the fact that a given 
individual cannot remove the device without causing bodily harm. Mr Graafstra 
indicated the problem with the VeriChip is the propensity for it to become engrained 
in tissue and muscle, and to become one with the body over a short period of time. 
Professor Kevin Warwick has also discussed this problem, after his Cyborg 1.0 
experiment which lasted only ten days. Others like the not-for-profit MedicAlert 
information service claim that it is unnecessary to embed an individual with a device 
when less-expensive non-invasive techniques abound. 
 
This leads to the ethical questions surrounding the technology and the potential for the 
technology to be used outside medical applications. Is it ethical to embed an 
individual with a device they cannot remove themselves, even if they are voluntarily 
subscribing to commercial service at a given point in time? What happens when an 
individual decides to opt-out of a VeriMed subscription after 12 months? Is the 
procedure painless or even possible? Who gets to decide who gets chipped, especially 
in the case of minors or those suffering from mental illness? And what of the potential 
for RFID, promoted as purely IDentification devices, when they are coupled with 
cellular or other satellite tracking network capabilities like global positioning systems 
(GPS)? There are a great number of unanswered questions here. What scientific 
endeavour has shown us historically, time and time again, is if something it possible, 
it is inevitable. 
 
While the VeriChip Corporation has documented an explicit privacy policy on its 
website, pertaining to implantable chips in humans, a privacy policy does not really 
address the total question of ethics. The company claims, “privacy is our ethical 
responsibility”, and while this paper does not refute the organisation’s intent, it does 
point out that privacy is merely one aspect of ethics. The VeriChip system, like any 
technology is not foolproof. Human error is ever present, and errors in data entry on 
the GVS may even have a detrimental effect on an incapacitated individual. And the 
VeriChip system is rendered useless if emergency services or hospitals are not 
adequately fitted with the right technology to read unique IDentification numbers. 
There are also all too common network disruptions, power failures, and other 
technical issues that render the implantable technology completely ineffective. Again, 
this is not to say that the technology cannot save lives but in its present form, there are 
obvious problems, many of which are bound to legislative concerns. The long-
standing debate over biometrics as unique identifiers have subsided more recently as 
legislators have ruled that given the level of intrusiveness of biometrics is minimal, 
i.e., it does not break the skin, it is permissible to be collected for the purposes of 
national security. 
 
One of the underlying issues of the VeriMed system is the control aspect. In 
VeriChip’s privacy policy it is outlined that “the content of the database itself [health 
records] and eligibility for access to the database are under the control of the VeriMed 
patient.” Control however is a separate matter to consent. The organisation also 
claims that the VeriMed is tamper-proof and loss-proof. This may be the case with the 
actual database but the actual chip implanted in the subscriber is not without 
tampering and loss. There have already been numerous RFID trials that show how a 
subscriber attack can render an RFID chip useless (e.g. ePassport), then what? Even 
during seemingly harmless information technology trade fairs, repeated warnings are 
noted to delegates who have pacemakers or cochlear implants to “not approach” 
certain exhibits. 
 
Today we have verified accounts of the VeriChip system being used for law 
enforcement personnel identification, VIP club lounge entry, as an anti-kidnapping 
technology, and even for employee physical secure access. Though these cases are 
admittedly limited, the potential for widespread use of microchip implants in humans 
is real and possible. The cost of getting a VeriChip is merely US$200 with an 
additional $10 monthly fee to store the information on the company’s web site. To 
early adopters of technology this would seem like another telecommunications 
subscription plan. 
 
This paper explores the ethical concerns related to semi-permanent implantable 
microchips for unique human identification. The paper uses secondary qualitative 
resources and three primary interviews with implantees to explore ethical issues. It 
also considers the potential for widespread adoption of RFID transponder implants, 
beyond voluntary subscription, or niche applications such as prison inmate tracking, 
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